# SPRO — Spero Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SPRO  
**Sources:** 19  
**Published:** 2026-08-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-spro-spero-therapeutics-inc-catalysts-narrative-risks-974

---

# Spero Therapeutics Inc (SPRO) — Research Summary as of August 28, 2026

## Company Overview

Spero Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2013, focused on developing novel treatments for rare diseases and diseases with high unmet need [[4]](https://www.merlintrader.com/spero-therapeutics-june2026-deepdive/)[[10]](https://investingnews.com/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update/). The company has historically centered its pipeline around multi-drug resistant (MDR) bacterial infections and has more recently pivoted toward an immunology pipeline [[1]](https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html)[[8]](https://www.stocktitan.net/news/SPRO/).

---

## Key Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-spro-spero-therapeutics-inc-catalysts-narrative-risks-974 (free to sign up)._